Search results for "Azepine"

showing 10 items of 266 documents

Changes in cytosolic calcium in response to noxious heat and their relationship to vanilloid receptors in rat dorsal root ganglion neurons.

2001

Heat transduction mechanisms in primary nociceptive afferents have been suggested to involve a vanilloid receptor channel with high calcium permeability. To characterize the changes in free cytosolic calcium evoked by noxious heat stimuli (< or =51 degrees C, 10s), we performed microfluorometric measurements in acutely dissociated small dorsal root ganglion neurons (< or =32.5 microm) of adult rats using the dye FURA-2. Only neurons that responded with a reversible increase in intracellular calcium to high potassium were evaluated. Heat-induced calcium transients (exceeding mean + 3S.D. of the temperature dependence of the dye) were found in 66 of 105 neurons. These transients increased non…

MaleHot Temperaturemedicine.drug_classReceptors Drugchemistry.chemical_elementPainCalcium channel blockerCalciumCalcium in biologyRats Sprague-Dawleychemistry.chemical_compoundCytosolGanglia SpinalmedicineAnimalsThermosensingCalcium SignalingNeurons AfferentCells CulturedFluorescent DyesCalcium metabolismVoltage-dependent calcium channelGeneral NeuroscienceMyocardiumT-type calcium channelNociceptorsRatschemistryBiochemistryCapsaicinBiophysicsPotassiumCalciumFemaleCalcium ChannelsCapsaicinCapsazepineFura-2Signal TransductionNeuroscience
researchProduct

Beta-carbolines as benzodiazepine receptor ligands II: Synthesis and benzodiazepine receptor affinity of beta-carboline-3-carboxylic acid amides.

1985

Numerous beta-carboline-3-carboxamides were synthesized by amidation of beta-carboline-3-carboxylic acid, with various amino acids and amino acid esters serving as amine components, and tested in respect to their affinity for the benzodiazepine receptor in mouse brain membranes. The title compounds have affinities in the low micromolar range. The results are discussed with respect to their relevance for a possible beta-carboline structure containing the endogenous ligand of the benzodiazepine receptor.

MaleIndolesChemical PhenomenaStereochemistrymedicine.drug_classPharmaceutical ScienceIn Vitro TechniquesLigandsMiceCarboline-3-carboxylic acidmedicineAnimalsReceptorchemistry.chemical_classificationBrain ChemistryBenzodiazepineReceptors GABA-AAffinitiesAmino acidChemistryKineticsMembranechemistryAmine gas treatingBenzodiazepine receptor ligandsCarbolinesJournal of pharmaceutical sciences
researchProduct

Neural overexcitation and implication of NMDA and AMPA receptors in a mouse model of temporal lobe epilepsy implying zinc chelation.

2006

Summary: Purpose: Zinc chelation with diethyldithiocarbamate (DEDTC) during nondamaging kainic acid administration enhances excitotoxicity to the level of cell damage. The objective of this work was to study the developing of the lesion in this model of temporal lobe epilepsy and the implications of the different types of glutamate receptors. Methods: The antagonist of the N-methyl-d-aspartate (NMDA) receptor MK-801, and the antagonist of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor GYKI52466, were used concomitantly with intraperitoneal administration of kainic acid (15 mg/kg) followed by DEDTC (150 mg/kg) in mouse. The animals were killed at different times from 4 …

MaleKainic acidmedicine.medical_specialtyExcitotoxicityHippocampusKainate receptorHSP72 Heat-Shock ProteinsAMPA receptorBiologymedicine.disease_causeHippocampusReceptors N-Methyl-D-AspartateSynaptic Transmissionchemistry.chemical_compoundBenzodiazepinesMiceReceptors Kainic AcidInternal medicinemedicineAnimalsReceptors AMPACell damageChelating AgentsKainic AcidCell DeathGlutamate receptormedicine.diseaseDisease Models AnimalZincEndocrinologyNeuroprotective Agentsnervous systemNeurologychemistryEpilepsy Temporal LobeNMDA receptorNeurology (clinical)Dizocilpine MaleateDitiocarbProto-Oncogene Proteins c-fosEpilepsia
researchProduct

Effects of risperidone and SCH 23390 on isolation-induced aggression in male mice.

1998

In this study, the antiaggressive effects of risperidone and SCH 23390 have been explored. Using the paradigm of isolation-induced aggression, 150 albino male mice of the OF1 strain were allocated to control and experimental groups which received three doses of risperidone (0.01, 0.05 and 0.1 mg/kg) or two doses of SCH 23390 (0.05 and 0.1 mg/kg). Only the highest doses of risperidone decreased threat and attack behaviours but all doses significantly impaired motor behaviour. SCH 23390 decreased attack with the two doses used and also produced significant increases in immobility. Although both antipsychotics are antiaggressive, this action seems to be more specific in the case of risperidone…

MaleMale micePharmacologyNeurotransmissionMotor Activitychemistry.chemical_compoundMiceSexual Behavior AnimalDopaminemedicineAnimalsPharmacology (medical)Biological PsychiatryPharmacologySCH-23390RisperidoneAggressionReceptors Dopamine D1BenzazepinesRisperidoneGroomingAggressionPsychiatry and Mental healthDopamine D2 Receptor AntagonistsNeurologychemistryIsolation induced aggressionSocial IsolationDepression ChemicalExploratory BehaviorDopamine AntagonistsFemaleNeurology (clinical)Serotoninmedicine.symptomPsychologymedicine.drugEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Role of the dopaminergic system in the acquisition, expression and reinstatement of MDMA-induced conditioned place preference in adolescent mice.

2012

Background The rewarding effects of 3,4-methylenedioxy-metamphetamine (MDMA) have been demonstrated in conditioned place preference (CPP) procedures, but the involvement of the dopaminergic system in MDMA-induced CPP and reinstatement is poorly understood. Methodology/Principal Findings In this study, the effects of the DA D1 antagonist SCH 23390 (0.125 and 0.250 mg/kg), the DA D2 antagonist Haloperidol (0.1 and 0.2 mg/kg), the D2 antagonist Raclopride (0.3 and 0.6 mg/kg) and the dopamine release inhibitor CGS 10746B (3 and 10 mg/kg) on the acquisition, expression and reinstatement of a CPP induced by 10 mg/kg of MDMA were evaluated in adolescent mice. As expected, MDMA significantly increa…

MaleMouseThiazepinesDopaminelcsh:MedicineStriatumPharmacologychemistry.chemical_compoundBehavioral NeuroscienceHabitsMiceHaloperidolMedicinePsychologylcsh:ScienceRacloprideSCH-23390MultidisciplinaryAnimal BehaviorDopaminergicMDMAAnimal ModelsNeurotransmittersMental HealthMedicinepsychological phenomena and processesmedicine.drugResearch ArticleSerotoninN-Methyl-34-methylenedioxyamphetamineBlotting WesternModel OrganismsAnimalsBiologyBehaviorbusiness.industrylcsh:RAntagonistBenzazepinesAdjustment (Psychology)Conditioned place preferencechemistrynervous systemRacloprideDevelopmental PsychologyConditioning OperantDopamine AntagonistsHaloperidollcsh:QbusinessZoologyNeurosciencePLoS ONE
researchProduct

Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury.

2010

The role of the endothelial contractile apparatus in the process of brain edema formation after brain trauma is not characterized. Phosphorylation of myosin light chains by myosin light chain kinases (MLCK) activates endothelial contractile elements and results in a rearrangement of the cytoskeleton. This may enhance post-traumatic blood-brain barrier dysfunction. In order to investigate the role of the MLCK on brain edema formation and blood-brain barrier permeability after brain injury, mice were anesthetized and subjected to a controlled cortical impact (CCI). MLCK expression is significantly up-regulated after CCI with a maximum 12 h post-injury. Specific inhibition of MLCK by ML-7 resu…

MaleMyosin light-chain kinaseMyosin Light ChainsTime FactorsEndotheliumIntracranial PressureTraumatic brain injuryCentral nervous systemBrain Edemamacromolecular substancesBrain damageNaphthalenesBlood–brain barrierBiochemistryNeuroprotectionDrug Administration ScheduleFunctional LateralityStatistics NonparametricCerebral edemaCellular and Molecular NeuroscienceMicemedicineAnimalsEnzyme InhibitorsMyosin-Light-Chain KinaseNeurologic Examinationbusiness.industryAzepinesmedicine.diseaseConstrictionCell biologyMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureGene Expression RegulationBlood-Brain BarrierBrain Injuriesmedicine.symptombusinessNeuroscienceEvans BlueJournal of neurochemistry
researchProduct

The dopamine release inhibitor CGS 10746B blocks conditioned physical signs of morphine withdrawal

2003

Environment previously paired with morphine withdrawal leads to conditioned physical signs of withdrawal, this effect being modulated by additional exposition to morphine administration. In this study, the putative role of dopamine in conditioned withdrawal signs is evaluated by administering the dopamine release inhibitor CGS 10746B prior to suffering two naloxone-induced withdrawals in a distinctive environment associated or not with morphine administration. The results show that dopamine seems to be necessary for the development of conditioned somatic signs of morphine withdrawal, as animals which received CGS 10746B do not present paw tremor or body shakes when they are placed in the en…

MaleNarcoticsPharmacologyBehavior AnimalMorphineNaloxoneThiazepinesNarcotic AntagonistsMedicine (miscellaneous)PharmacologySubstance Withdrawal SyndromeMicePsychiatry and Mental healthMorphine withdrawalDopamineConditioning PsychologicalMorphinemedicineAnimalsConditioningSocial BehaviorPsychologymedicine.drugAddiction Biology
researchProduct

Lack of Specific Effects of Selective D1 and D2 Dopamine Antagonists vs. Risperidone on Morphine-Induced Hyperactivity

2000

Abstract RODRIGUEZ-ARIAS, M., I. BROSETA, M. A. AGUILAR AND J. MINARRO. Lack of specific effects of selective D 1 and D 2 dopamine antagonists on morphine-induced hyperactivity. PHARMACOL BIOCHEM BEHAV 66 (1) 189–197, 2000.—In the present study, three different dopamine antagonists were challenged in order to counteract hyperactivity induced by 50 mg/kg of morphine. A wide range of doses of morphine (50, 25, 12.5, 6.25, or 3.12 mg/kg) were evaluated on spontaneous locomotor activity. A significant increase was observed only with the two higher doses tested (25 and 50 mg/kg). No decrease was found with any of the doses used at any period of time. After analyzing doses of SCH 23390 (0.5, 0.1,…

MaleNarcoticsmedicine.medical_specialtyClinical BiochemistryMotor ActivityPharmacologyCatalepsyToxicologyBiochemistryMiceBehavioral Neurosciencechemistry.chemical_compoundDopamineInternal medicinemedicineAnimalsBiological PsychiatryPharmacologyRacloprideCatalepsySCH-23390RisperidoneMorphineChemistryReceptors Dopamine D1AntagonistDopamine antagonistBenzazepinesRisperidonemedicine.diseaseDopamine D2 Receptor AntagonistsEndocrinologyRacloprideMorphineDopamine Antagonistsmedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Effects of SCH 23390, Raclopride, and Haloperidol on Morphine Withdrawal-Induced Aggression in Male Mice

1999

Abstract RODRIGUEZ-ARIAS, M., J. PINAZO, J. MINARRO AND L. STINUS. Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice. PHARMACOL BIOCHEM BEHAV 64(1) 123–130, 1999.—Dopamine seems to play a very important role in aggressive behavior observed in morphine withdrawal. The effect of SCH 23390 (0.5 mg/kg), raclopride (0.3 mg/kg), and haloperidol (0.1 mg/kg) on morphine withdrawal-induced aggression has been studied in this work. Mice were rendered dependent by a daily injection of morphine (2.5 mg/kg) for 14 days. Three different experiments were carried out with the objective to evaluate the antiaggressive effect of the dopamine antagonists o…

MaleNarcoticsmedicine.medical_specialtyNarcotic AntagonistsClinical BiochemistryPharmacologyToxicologyBiochemistryMiceBehavioral Neurosciencechemistry.chemical_compoundDopamineInternal medicineSalicylamidesmedicineHaloperidolAnimalsSocial BehaviorBiological PsychiatryPharmacologyRacloprideSCH-23390MorphineNaloxonebusiness.industryDopaminergicAntagonistDopamine antagonistBenzazepinesSubstance Withdrawal SyndromeAggressionEndocrinologychemistryRacloprideMorphineDopamine AntagonistsHaloperidolbusinessAntipsychotic Agentsmedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Treatments used for obsessive-compulsive disorder-An international perspective.

2018

Objective The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive–compulsive disorder (OCD). Methods Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated. Results The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13…

MaleObsessive-Compulsive DisorderInternationalitymedicine.medical_treatmentDeep Brain StimulationSocial SciencesFluvoxamineBENZODIAZEPINASpharmacotherapyBenzodiazepines0302 clinical medicinePharmacology (medical)TERAPIA PSICOANALITICAPSICOFARMACOLOGIAantipsychotics; benzodiazepines; cross-cultural study; obsessive-compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsMiddle Aged3. Good healthExposure and response preventionantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsNeurologyPsychiatry and Mental HealthSerotonin Uptake Inhibitorscross-cultural studyAripiprazoleFemalebenzodiazepineSelective Serotonin Reuptake Inhibitorsmedicine.drugPsychosurgeryAntipsychotic AgentsAdultmedicine.medical_specialty:Ciências da Saúde [Ciências Médicas]Ciências Médicas::Ciências da SaúdeSerotonin reuptake inhibitor03 medical and health sciencesANTIPSICOTICOSobsessive–compulsive disorderselective serotonin reuptake inhibitorsmedicinePSICOTROPICOSHumansAntipsychoticPsychiatryFARMACOTERAPIAFluoxetineRisperidoneantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitors; Neurology; Neurology (clinical); Psychiatry and Mental Health; Pharmacology (medical)Science & Technologyselective serotonin reuptake inhibitorbusiness.industryTRASTORNO OBSESIVO COMPULSIVO030227 psychiatryantipsychoticPsychosurgeryantipsychoticsNeurology (clinical)business030217 neurology & neurosurgerySEROTONINAHuman psychopharmacology
researchProduct